Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356520 | 0.88 | HSD17B10 (0.48) | HSD17B10THRBMEN1KMT2AKDM4E | |
| SCHEMBL1356434 | 0.87 | MEN1 (0.47) | HSD17B10THRBMEN1KMT2AKDM4E | |
| SCHEMBL12135175 | 0.87 | ALOX15 (0.60) | HSD17B10THRBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1357410 | 0.86 | KMT2A (0.50) | HSD17B10THRBMEN1KMT2AKDM4E | |
| SCHEMBL1354990 | 0.86 | MEN1 (0.47) | HSD17B10THRBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12135462 | 0.86 | SIRT2 (0.55) | HSD17B10THRBHTTMEN1KMT2A | |
| SCHEMBL1356817 | 0.86 | PTGER4 (0.49) | HSD17B10THRBHTTMEN1KMT2A | |
| SCHEMBL12135414 | 0.85 | HSD17B10 (0.46) | HSD17B10THRBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1357620 | 0.85 | THRB (0.53) | HSD17B10THRBMEN1KMT2AKDM4E | |
| SCHEMBL12135453 | 0.85 | HSD17B10 (0.48) | HSD17B10THRBMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190826-A1 | BENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-07-29 | — | — | US | claimed |
| EP-2172454-A1 | BENZIMIDAZOLE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | claimed |
| US-20110282066-A1 | SCREENING METHOD FOR SUBSTANCE USEFUL AS AGENT FOR TREATING PROSTATE CANCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| US-20110282066-A1 | SCREENING METHOD FOR SUBSTANCE USEFUL AS AGENT FOR TREATING PROSTATE CANCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| US-20110282066-A1 | SCREENING METHOD FOR SUBSTANCE USEFUL AS AGENT FOR TREATING PROSTATE CANCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| EP-2383573-A1 | SCREENING METHOD FOR SUBSTANCE USEFUL AS AGENT FOR TREATING PROSTATE CANCER | Astellas Pharma Inc. (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-20100190826-A1 | BENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190826-A1 | BENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190826-A1 | BENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2172454-A1 | BENZIMIDAZOLE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282066-A1 | SCREENING METHOD FOR SUBSTANCE USEFUL AS AGENT FOR TREATING PROSTATE CANCER | CYP17A1, KLK3, NR5A1 | HSD17B10 32/4885THRB 777/4885HTT 4195/4885 |
| US-20100190826-A1 | BENZIMIDAZOLE DERIVATIVE | SHBG, SRD5A1, AR | HSD17B10 34/4885THRB 503/4885HTT 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.